CAMBRIDGE, Mass., Feb. 4, 2013 /PRNewswire/ -- Epizyme, Inc., a biopharmaceutical company leading the creation of personalized therapeutics to treat patients with genetically defined cancers, today announced its participation in three upcoming conferences.
"Epizyme looks forward to meeting with the scientific community and investors to present the foundations of our clinical platform for the development of personalized therapeutics and companion diagnostics to treat genetically defined cancers," said Robert Gould, President and CEO, Epizyme. "We'll address how our focus on the genetic drivers of cancer leads to quicker, more efficient drug development, pairing the right medicines with the right patients to create a personalized approach to cancer treatment."
Epizyme is leading the creation of small molecule histone methyltransferase inhibitors (HMTi), a new class of personalized therapeutics for patients with genetically defined cancers. Genetic alterations in HMTs, a family of epigenetic enzymes, drive multiple human diseases. Our approach represents the future of healthcare by matching better medicines with the right patients.
Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). For more information, visit www.epizyme.com.
Copyright©2012 PR Newswire.
All rights reserved